Department of Cardiology, Children's Hospital of Soochow University, Suzhou, 215003, China.
Institute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, China.
Eur J Pediatr. 2018 Aug;177(8):1279-1292. doi: 10.1007/s00431-018-3182-2. Epub 2018 Jun 8.
The purpose of this study was to identify the clinical features and laboratory factors that are predictive of intravenous immunoglobulin (IVIG)-resistant Kawasaki disease. Multiple databases were searched for relevant studies on IVIG-resistant Kawasaki disease published from January 2002 to April 2017. Eligible studies were retrieved by manual review of the references. Stata 12 was used for the meta-analysis. Weighted mean differences and odds ratios with 95% confidence intervals were calculated for several indices. Twenty-eight studies involving 26,260 patients comprising 4442 IVIG-resistant Kawasaki disease patients and 21,818 IVIG-sensitive Kawasaki disease patients were included. The meta-analysis showed that the erythrocyte sedimentation rate (ESR) in the IVIG-resistant group was significantly higher than that in the IVIG-sensitive group, and that platelet count and hemoglobin levels were significantly lower in the IVIG-resistant group. The patients with oral mucosa alterations, cervical lymphadenopathy, swelling of the extremities, polymorphous rash, and initial administration of IVIG ≤ 4.0 days after the onset of symptoms were more likely to be IVIG resistant.
The initial administration of IVIG ≤ 4.0 days after the onset of symptoms increased ESR and decreased hemoglobin and platelet counts, oral mucosa alterations, cervical lymphadenopathy, swelling of the extremities, and polymorphous rash and are the risk factors for IVIG-resistant Kawasaki disease. What is Known: • Recent reports on this topic are about aspartate aminotransferase (AST), alanine aminotransferase (ALT), gammaglutamyl transferase, total bilirubin, white blood cells, platelets, erythrocyte sedimentation rate (ESR), polymorphonuclear leukocytes (PMN), C-reactive protein (CRP), pro-brain natriuretic peptide (BNP), albumin, and sodium as the risk factors in the IVIG-resistant Kawasaki disease; however, no studies have been published on clinical features as predictors of IVIG resistance. What is New: • This meta-analysis identified the clinical features, the initial administration of IVIG ≤ 4.0 days after the onset of symptoms, and much more comprehensive laboratory indicators, such as hemoglobin, as predictors of IVIG-resistant Kawasaki disease.
本研究旨在确定预测静脉注射免疫球蛋白(IVIG)抵抗川崎病的临床特征和实验室因素。从 2002 年 1 月至 2017 年 4 月,我们通过多个数据库检索了有关 IVIG 抵抗川崎病的相关研究。通过手动审查参考文献来检索合格的研究。Stata 12 用于荟萃分析。计算了几个指标的加权均数差异和优势比及其 95%置信区间。共纳入 28 项研究,涉及 26260 例患者,其中 4442 例为 IVIG 抵抗川崎病患者,21818 例为 IVIG 敏感川崎病患者。荟萃分析显示,IVIG 抵抗组的红细胞沉降率(ESR)明显高于 IVIG 敏感组,IVIG 抵抗组的血小板计数和血红蛋白水平明显较低。口腔黏膜改变、颈部淋巴结肿大、四肢肿胀、多形性皮疹和症状发作后 4.0 天内初始 IVIG 治疗的患者更可能对 IVIG 抵抗。
症状发作后 4.0 天内初始 IVIG 治疗可增加 ESR,降低血红蛋白和血小板计数,口腔黏膜改变、颈部淋巴结肿大、四肢肿胀、多形性皮疹,是 IVIG 抵抗川崎病的危险因素。
• 关于这一主题的最新报告涉及天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)、γ-谷氨酰转移酶、总胆红素、白细胞、血小板、红细胞沉降率(ESR)、中性粒细胞(PMN)、C 反应蛋白(CRP)、脑钠肽前体(BNP)、白蛋白和钠作为 IVIG 抵抗川崎病的危险因素;然而,尚无研究报道将临床特征作为 IVIG 抵抗的预测因子。
• 这项荟萃分析确定了临床特征,即症状发作后 4.0 天内初始 IVIG 治疗以及更全面的实验室指标,如血红蛋白,作为 IVIG 抵抗川崎病的预测因子。